Stay updated with breaking news from Subjects With. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and...
Chiesi, the international research-focused biopharmaceutical and healthcare group, has announced that its phase III clinical safety trial for the development of an innovative carbon minimal inhaler platform is underway.1 The carbon minimal inhaler will replace the current hydrofluorocarbon propellant (HFC 134a) ...
/PRNewswire/ -- Riboscience, LLC, today announced the first presentation of data from the ongoing Phase 1 clinical trial of the ENPP1 inhibitor RBS2418 that...
Was conducted to examine the efficacy of fenfluramine on GTCS reduction in various types of Developmental and Epileptic Encephalopathies or rare epilepsy conditions. Data from 13 studies , 4...
On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...